Dezocine

	WikiDoc Resources for Dezocine
Articles
Most recent articles on Dezocine Most cited articles on Dezocine Review articles on Dezocine Articles on Dezocine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dezocine Images of Dezocine Photos of Dezocine Podcasts & MP3s on Dezocine Videos on Dezocine
Evidence Based Medicine
Cochrane Collaboration on Dezocine Bandolier on Dezocine TRIP on Dezocine
Clinical Trials
Ongoing Trials on Dezocine at Clinical Trials.gov Trial results on Dezocine Clinical Trials on Dezocine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dezocine NICE Guidance on Dezocine NHS PRODIGY Guidance FDA on Dezocine CDC on Dezocine
Books
Books on Dezocine
News
Dezocine in the news Be alerted to news on Dezocine News trends on Dezocine
Commentary
Blogs on Dezocine
Definitions
Definitions of Dezocine
Patient Resources / Community
Patient resources on Dezocine Discussion groups on Dezocine Patient Handouts on Dezocine Directions to Hospitals Treating Dezocine Risk calculators and risk factors for Dezocine
Healthcare Provider Resources
Symptoms of Dezocine Causes & Risk Factors for Dezocine Diagnostic studies for Dezocine Treatment of Dezocine
Continuing Medical Education (CME)
CME Programs on Dezocine
International
Dezocine en Espanol Dezocine en Francais
Business
Dezocine in the Marketplace Patents on Dezocine
Experimental / Informatics
List of terms related to Dezocine

Dezocine
Clinical data
Synonyms	Dezocine, Dalgan
Routes of; administration	intramuscular injection
ATC code	N02AX03 (WHO) ;
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	2.2 hours
Identifiers
	IUPAC name (5α,11α,13S)-13-amino-5,6,7,8,9,10,11,12-octahydro -5-methyl-5,11-methanobenzocyclodecen-3-ol;
CAS Number	53648-55-8;
PubChem CID	40841;
DrugBank	APRD00912;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C16H23NO
Molar mass	245.36 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dezocine (Dalgan, WY-16225) is an opioid analgesic related to pentazocine, with a similar profile of effects that include analgesic action and euphoria at low doses,^[1] but produces dysphoria and hallucinations at high doses, most likely due to action at κ-opioid receptors.^[2]^[3]

Dezocine has been found to be an effective painkiller comparable to meperidine (pethidine),^[4] and so is a more effective analgesic than pentazocine, but causes relatively more respiratory depression than pentazocine.^[5] It is a useful drug for the treatment of pain,^[6] but side effects such as dizziness limit its clinical application,^[7] and it can produce opioid withdrawal syndrome in patients already dependent on other opioids.^[8]

Dezocine is unusual among opioids as it is the only primary amine known to be an active opioid. It is a mixed agonist-antagonist as with other drugs in this class,^[9] and despite having a stronger respiratory depressant effect than morphine, dezocine shows a ceiling effect on its respiratory depressive action so above a certain dose this effect does not get any more severe.^[10]

Template:Pharm-stub

References

↑ Zacny JP, Lichtor JL, de Wit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesthesia and Analgesia. 1992 Apr;74(4):523-30.
↑ Jacobs AM, Youngblood F. Opioid receptor affinity for agonist-antagonist analgesics. Journal of the American Podiatric Medical Association. 1992 Oct;82(10):520-4.
↑ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacology. 2006 Jan 25;6:3.
↑ Camu F, Gepts E. Analgesic properties of dezocine for relief of postoperative pain. Acta Anaesthesiologica Belgica. 1979;30 Suppl:183-91.
↑ Wuest HP, Bellville JW. The respiratory effects of dezocine and pentazocine in man. Journal of Clinical Pharmacology. 1979 Apr;19(4):205-10.
↑ O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48.
↑ Oosterlinck W, Verbaeys A. Preliminary clinical experience with dezocine, a new potent analgesic. Current Medical Research and Opinion. 1980;6(7):472-4.
↑ Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans. Clinical Pharmacology and Therapeutics. 1996 Aug;60(2):206-17.
↑ Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. Journal Pharmacology and Experimental Therapeutics. 1984 Apr;229(1):118-26.
↑ Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clinical Pharmacology and Therapeutics. 1984 Mar;35(3):367-73.

Template:Opioids

[1] Zacny JP, Lichtor JL, de Wit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesthesia and Analgesia. 1992 Apr;74(4):523-30.

[2] Jacobs AM, Youngblood F. Opioid receptor affinity for agonist-antagonist analgesics. Journal of the American Podiatric Medical Association. 1992 Oct;82(10):520-4.

[3] Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacology. 2006 Jan 25;6:3.

[4] Camu F, Gepts E. Analgesic properties of dezocine for relief of postoperative pain. Acta Anaesthesiologica Belgica. 1979;30 Suppl:183-91.

[5] Wuest HP, Bellville JW. The respiratory effects of dezocine and pentazocine in man. Journal of Clinical Pharmacology. 1979 Apr;19(4):205-10.

[6] O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48.

[7] Oosterlinck W, Verbaeys A. Preliminary clinical experience with dezocine, a new potent analgesic. Current Medical Research and Opinion. 1980;6(7):472-4.

[8] Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans. Clinical Pharmacology and Therapeutics. 1996 Aug;60(2):206-17.

[9] Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. Journal Pharmacology and Experimental Therapeutics. 1984 Apr;229(1):118-26.

[10] Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clinical Pharmacology and Therapeutics. 1984 Mar;35(3):367-73.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Clinical data

Synonyms	Dezocine, Dalgan
Routes of administration	intramuscular injection
ATC code	N02AX03 (WHO)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	2.2 hours
Identifiers
IUPAC name (5α,11α,13S)-13-amino-5,6,7,8,9,10,11,12-octahydro -5-methyl-5,11-methanobenzocyclodecen-3-ol
CAS Number	53648-55-8
PubChem CID	40841
DrugBank	APRD00912
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₆H₂₃NO
Molar mass	245.36 g/mol

Dezocine

Overview

References

Navigation menu